Efavirenz directly modulates the oestrogen receptor and induces breast cancer cell growth

M. J. Sikora, J. M. Rae, M. D. Johnson, Zeruesenay Desta

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Objectives: Efavirenz-based HIV therapy is associated with breast hypertrophy and gynaecomastia. Here, we tested the hypothesis that efavirenz induces gynaecomastia through direct binding and modulation of the oestrogen receptor (ER). Methods: To determine the effect of efavirenz on growth, the oestrogen-dependent, ER-positive breast cancer cell lines MCF-7, T47D and ZR-75-1 were treated with efavirenz under oestrogen-free conditions in the presence or absence of the anti-oestrogen ICI 182,780. Cells treated with 17β-oestradiol in the absence or presence of ICI 182,780 served as positive and negative controls, respectively. Cellular growth was assayed using the crystal violet staining method and an in vitro receptor binding assay was used to measure the ER binding affinity of efavirenz. Results: Efavirenz induced growth in MCF-7 cells with an estimated effective concentration for half-maximal growth (EC50) of 15.7 μM. This growth was reversed by ICI 182,780. Further, efavirenz binds directly to the ER [inhibitory concentration for half maximal binding (IC50) of ∼52 μM] at a roughly 1000-fold higher concentration than observed with 17β-oestradiol. Conclusions: Our data suggest that efavirenz-induced gynaecomastia may be caused, at least in part, by drug-induced ER activation in breast tissues.

Original languageEnglish
Pages (from-to)603-607
Number of pages5
JournalHIV Medicine
Volume11
Issue number9
DOIs
StatePublished - Oct 2010

Fingerprint

efavirenz
Estrogen Receptors
Breast Neoplasms
Growth
Estrogens
Estradiol
Breast
Gentian Violet
MCF-7 Cells
Hypertrophy
Inhibitory Concentration 50

Keywords

  • Efavirenz
  • Gynaecomastia
  • Highly active antiretroviral therapy
  • Oestrogen receptor
  • Oestrogens

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)
  • Health Policy

Cite this

Efavirenz directly modulates the oestrogen receptor and induces breast cancer cell growth. / Sikora, M. J.; Rae, J. M.; Johnson, M. D.; Desta, Zeruesenay.

In: HIV Medicine, Vol. 11, No. 9, 10.2010, p. 603-607.

Research output: Contribution to journalArticle

Sikora, M. J. ; Rae, J. M. ; Johnson, M. D. ; Desta, Zeruesenay. / Efavirenz directly modulates the oestrogen receptor and induces breast cancer cell growth. In: HIV Medicine. 2010 ; Vol. 11, No. 9. pp. 603-607.
@article{a3ac0357e7c94f0f90979dbbb0fec81e,
title = "Efavirenz directly modulates the oestrogen receptor and induces breast cancer cell growth",
abstract = "Objectives: Efavirenz-based HIV therapy is associated with breast hypertrophy and gynaecomastia. Here, we tested the hypothesis that efavirenz induces gynaecomastia through direct binding and modulation of the oestrogen receptor (ER). Methods: To determine the effect of efavirenz on growth, the oestrogen-dependent, ER-positive breast cancer cell lines MCF-7, T47D and ZR-75-1 were treated with efavirenz under oestrogen-free conditions in the presence or absence of the anti-oestrogen ICI 182,780. Cells treated with 17β-oestradiol in the absence or presence of ICI 182,780 served as positive and negative controls, respectively. Cellular growth was assayed using the crystal violet staining method and an in vitro receptor binding assay was used to measure the ER binding affinity of efavirenz. Results: Efavirenz induced growth in MCF-7 cells with an estimated effective concentration for half-maximal growth (EC50) of 15.7 μM. This growth was reversed by ICI 182,780. Further, efavirenz binds directly to the ER [inhibitory concentration for half maximal binding (IC50) of ∼52 μM] at a roughly 1000-fold higher concentration than observed with 17β-oestradiol. Conclusions: Our data suggest that efavirenz-induced gynaecomastia may be caused, at least in part, by drug-induced ER activation in breast tissues.",
keywords = "Efavirenz, Gynaecomastia, Highly active antiretroviral therapy, Oestrogen receptor, Oestrogens",
author = "Sikora, {M. J.} and Rae, {J. M.} and Johnson, {M. D.} and Zeruesenay Desta",
year = "2010",
month = "10",
doi = "10.1111/j.1468-1293.2010.00831.x",
language = "English",
volume = "11",
pages = "603--607",
journal = "HIV Medicine",
issn = "1464-2662",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Efavirenz directly modulates the oestrogen receptor and induces breast cancer cell growth

AU - Sikora, M. J.

AU - Rae, J. M.

AU - Johnson, M. D.

AU - Desta, Zeruesenay

PY - 2010/10

Y1 - 2010/10

N2 - Objectives: Efavirenz-based HIV therapy is associated with breast hypertrophy and gynaecomastia. Here, we tested the hypothesis that efavirenz induces gynaecomastia through direct binding and modulation of the oestrogen receptor (ER). Methods: To determine the effect of efavirenz on growth, the oestrogen-dependent, ER-positive breast cancer cell lines MCF-7, T47D and ZR-75-1 were treated with efavirenz under oestrogen-free conditions in the presence or absence of the anti-oestrogen ICI 182,780. Cells treated with 17β-oestradiol in the absence or presence of ICI 182,780 served as positive and negative controls, respectively. Cellular growth was assayed using the crystal violet staining method and an in vitro receptor binding assay was used to measure the ER binding affinity of efavirenz. Results: Efavirenz induced growth in MCF-7 cells with an estimated effective concentration for half-maximal growth (EC50) of 15.7 μM. This growth was reversed by ICI 182,780. Further, efavirenz binds directly to the ER [inhibitory concentration for half maximal binding (IC50) of ∼52 μM] at a roughly 1000-fold higher concentration than observed with 17β-oestradiol. Conclusions: Our data suggest that efavirenz-induced gynaecomastia may be caused, at least in part, by drug-induced ER activation in breast tissues.

AB - Objectives: Efavirenz-based HIV therapy is associated with breast hypertrophy and gynaecomastia. Here, we tested the hypothesis that efavirenz induces gynaecomastia through direct binding and modulation of the oestrogen receptor (ER). Methods: To determine the effect of efavirenz on growth, the oestrogen-dependent, ER-positive breast cancer cell lines MCF-7, T47D and ZR-75-1 were treated with efavirenz under oestrogen-free conditions in the presence or absence of the anti-oestrogen ICI 182,780. Cells treated with 17β-oestradiol in the absence or presence of ICI 182,780 served as positive and negative controls, respectively. Cellular growth was assayed using the crystal violet staining method and an in vitro receptor binding assay was used to measure the ER binding affinity of efavirenz. Results: Efavirenz induced growth in MCF-7 cells with an estimated effective concentration for half-maximal growth (EC50) of 15.7 μM. This growth was reversed by ICI 182,780. Further, efavirenz binds directly to the ER [inhibitory concentration for half maximal binding (IC50) of ∼52 μM] at a roughly 1000-fold higher concentration than observed with 17β-oestradiol. Conclusions: Our data suggest that efavirenz-induced gynaecomastia may be caused, at least in part, by drug-induced ER activation in breast tissues.

KW - Efavirenz

KW - Gynaecomastia

KW - Highly active antiretroviral therapy

KW - Oestrogen receptor

KW - Oestrogens

UR - http://www.scopus.com/inward/record.url?scp=77956415880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956415880&partnerID=8YFLogxK

U2 - 10.1111/j.1468-1293.2010.00831.x

DO - 10.1111/j.1468-1293.2010.00831.x

M3 - Article

C2 - 20408889

AN - SCOPUS:77956415880

VL - 11

SP - 603

EP - 607

JO - HIV Medicine

JF - HIV Medicine

SN - 1464-2662

IS - 9

ER -